FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products

Contributed by: Business Wire

Logo

Tags

Oncology

Retail

Health

FDA

Tobacco

Other Health

Cardiology

More Like This

Philip Morris International Urges FDA Advisory Committee to Recommend Authorizing ZYN as a Modified Risk Tobacco Product

FDA Authorizes All ZYN Nicotine Pouch Products Currently Marketed by Swedish Match in the U.S.

Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product

Philip Morris International Urges U.S. Food and Drug Administration Advisory Committee to Recommend Continued Marketing of IQOS as Modified Risk Product

Philip Morris International Expands its Partnership with Scuderia Ferrari HP, Launching a Bold New Chapter in Their Long-Standing Relationship

Philip Morris International Expands its Partnership with Ducati Corse as Decades-Long Partnership Races Forward with Purpose

Swedish Match USA, Inc. Presents to U.S. Food and Drug Administration Advisory Committee to Renew Modified Risk Claim for General Snus

Production of ZYN oral nicotine pouches at the Swedish Match Owensboro, Ky., facility. (Photo: Business Wire)

Philip Morris International U.S. Affiliate to Create 500 Jobs Investing $600 Million in Aurora, Colo., Manufacturing Facility